Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

New treatment for Crohn’s disease launched

bs_subtitle

A new treatment option for adult patients with moderately to severely active Crohn’s disease has been launched in the UK. Ustekinumab (Stelara) is for patients who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies. With no known cure, the aim of treatment for Crohn’s disease is to stop the inflammatory process, relieve symptoms (induce and maintain remission) and avoid surgery wherever possible. Ustekinumab is the first biologic therapy for Crohn’s disease targeting interleukin (IL)-12 and IL-23 cytokines, which play a key role

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy